HSK disease cause greater HOAs

Article

Eyes with a history of herpes simplex keratitis (HSK) have significantly greater higher order aberrations (HOAs) than eyes with no past history of the disease, according to a paper.

Eyes with a history of herpes simplex keratitis (HSK) have significantly greater higher order aberrations (HOAs) than eyes with no past history of the disease, according to a paper.

Professor Marc Labetoulle et al., Service d'Ophtalmologie, Hopital Bicêtre, APHP, Université Paris, France, enrolled 15 patients with a history of recurrent unilateral HSK and normal Snellen visual acuity. The eyes were statically compared with normal fellow eyes (control group) and HOA, modulation transfer function (MTF) and Strehl ratio were measured using the OPD-SCAN II aberrometer. The measurements were performed at least 3 months after the last case of herpes.

The HSK group presented with significantly higher total HOA, trefoil and tetrafoil, compared to the control group. The HSK group also had significantly lower MTF and Strehl ratio compared to the control group. Eyes with corneal opacities in the HSK group tended to have greater optical aberrations than eyes with clear cornea.

There were greater HOAs in the eyes with a HSK history and this could explain some of the visual complaints of HSK. This includes decrease in contrast quality or reduced colour perception.

Please visit the British Journal of Ophthalmology to read the abstract.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.